PDCD11 is a nucleolar protein with emerging roles in both normal cellular processes and cancer pathogenesis. Originally characterized for involvement in ribosomal RNA biogenesis [NCBI annotation], PDCD11 localizes to the nucleus, nucleolus, and nucleoplasm where it binds RNA and proteins including NF-κB [GO annotations]. Recent evidence reveals critical cancer-promoting functions: PDCD11 stabilizes the C-MYC oncoprotein by preventing SKP2-mediated C-MYC ubiquitination in p53-mutant breast and colon cancers, promoting proliferation and metastasis 1. In hepatocellular carcinoma, PDCD11 functions as a carrier of hepatitis B viral RNA within extracellular vesicles, facilitating viral spread 2. Circulating PDCD11 RNA serves as a biomarker: low preinduction levels predict successful vaginal birth after labor induction 3, while elevated circ-PDCD11 in lung large-cell carcinoma correlates with poor survival and metastasis 4. PDCD11 also participates in DNA damage responses through interaction with Exonuclease-1, affecting cellular resistance to DNA-damaging agents 5. Notably, rare PDCD11 variants showed no association with schizophrenia risk 6. These findings establish PDCD11 as a multifunctional protein with significant implications for cancer progression and potential as a therapeutic target for C-MYC-driven malignancies.